Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 7 |
List of Tables | 7 | 1 |
List of Figures | 8 | 1 |
Introduction | 9 | 1 |
Global Markets Direct Report Coverage | 9 | 1 |
Bipolar Disorder (Manic Depression) Overview | 10 | 1 |
Therapeutics Development | 11 | 2 |
Pipeline Products for Bipolar Disorder (Manic Depression) Overview | 11 | 1 |
Pipeline Products for Bipolar Disorder (Manic Depression) Comparative Analysis | 12 | 1 |
Bipolar Disorder (Manic Depression) Therapeutics under Development by Companies | 13 | 2 |
Bipolar Disorder (Manic Depression) Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
Bipolar Disorder (Manic Depression) Pipeline Products Glance | 16 | 3 |
Late Stage Products | 16 | 1 |
Clinical Stage Products | 17 | 1 |
Early Stage Products | 18 | 1 |
Bipolar Disorder (Manic Depression) Products under Development by Companies | 19 | 2 |
Bipolar Disorder (Manic Depression) Products under Investigation by Universities/Institutes | 21 | 1 |
Bipolar Disorder (Manic Depression) Companies Involved in Therapeutics Development | 22 | 20 |
Aequus Pharmaceuticals Inc. | 22 | 1 |
Amorsa Therapeutics Inc. | 23 | 1 |
AstraZeneca Plc | 24 | 1 |
Biogen Inc | 25 | 1 |
Delpor, Inc. | 26 | 1 |
Intas Pharmaceuticals Ltd. | 27 | 1 |
Intra-Cellular Therapies, Inc. | 28 | 1 |
Johnson &Johnson | 29 | 1 |
KemPharm, Inc. | 30 | 1 |
Mapi Pharma Ltd. | 31 | 1 |
Navya Biologicals Pvt Ltd | 32 | 1 |
Neurocrine Biosciences Inc | 33 | 1 |
Omeros Corporation | 34 | 1 |
Otsuka Holdings Co., Ltd. | 35 | 1 |
Pfizer Inc. | 36 | 1 |
Reviva Pharmaceuticals Inc. | 37 | 1 |
SK Biopharmaceuticals Co., Ltd. | 38 | 1 |
Sumitomo Dainippon Pharma Co Ltd | 39 | 1 |
Zogenix, Inc. | 40 | 1 |
Zysis Limited | 41 | 1 |
Bipolar Disorder (Manic Depression) Therapeutics Assessment | 42 | 10 |
Assessment by Monotherapy Products | 42 | 1 |
Assessment by Combination Products | 43 | 1 |
Assessment by Target | 44 | 2 |
Assessment by Mechanism of Action | 46 | 2 |
Assessment by Route of Administration | 48 | 2 |
Assessment by Molecule Type | 50 | 2 |
Drug Profiles | 52 | 52 |
(cycloserine + lurasidone hydrochloride) Drug Profile | 52 | 1 |
aripiprazole Drug Profile | 53 | 2 |
aripiprazole CR Drug Profile | 55 | 1 |
aripiprazole ER Drug Profile | 56 | 1 |
CB-1407 Drug Profile | 57 | 1 |
CB-2803 Drug Profile | 58 | 1 |
Cenobamate Drug Profile | 59 | 2 |
CNV-1061436 Drug Profile | 61 | 1 |
ebselen Drug Profile | 62 | 1 |
Endoxifen Drug Profile | 63 | 2 |
ITI-007 Drug Profile | 65 | 9 |
JNJ-18038683 Drug Profile | 74 | 1 |
KP-303 Drug Profile | 75 | 1 |
lurasidone hydrochloride Drug Profile | 76 | 8 |
NAV-003 Drug Profile | 84 | 1 |
paliperidone palmitate Drug Profile | 85 | 1 |
PGW-5 Drug Profile | 86 | 1 |
quetiapine fumarate ER Drug Profile | 87 | 1 |
risperidone Drug Profile | 88 | 2 |
risperidone Drug Profile | 90 | 1 |
risperidone Drug Profile | 91 | 1 |
RP-5063 Drug Profile | 92 | 2 |
SKL-PSY Drug Profile | 94 | 1 |
Small Molecule for Bipolar Disorder Drug Profile | 95 | 1 |
Small Molecule for Cancer and Neurodegenerative Disease Drug Profile | 96 | 1 |
Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia Drug Profile | 97 | 1 |
Small Molecule to Inhibit VMAT-2 for Bipolar Disorder, Movement Disorders and Schizophrenia Drug Profile | 98 | 1 |
Small Molecule to Target GPR50 for Bipolar Disorder and Metabolic Disorders Drug Profile | 99 | 1 |
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System Drug Profile | 100 | 1 |
Small Molecules to Target NMDA Receptor for Bipolar Depression Drug Profile | 101 | 1 |
Synthetic Peptides to Inhibit IMPase for Bipolar Disorder Drug Profile | 102 | 1 |
ziprasidone mesylate Drug Profile | 103 | 1 |
Bipolar Disorder (Manic Depression) Dormant Projects | 104 | 3 |
Bipolar Disorder (Manic Depression) Discontinued Products | 107 | 1 |
Bipolar Disorder (Manic Depression) Product Development Milestones | 108 | 13 |
Featured News &Press Releases | 108 | 1 |
Oct 27, 2016: Sunovion Announces Positive Clinical Study Results for Latuda (lurasidone HCl) in Adolescents with Schizophrenia | 108 | 1 |
Oct 18, 2016: NeuroRx Solidifies Intellectual Property Position Receives Notice of Allowance by US Patent Office | 109 | 1 |
Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress | 110 | 1 |
Aug 09, 2016: Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan | 111 | 1 |
Jun 01, 2016: NeuroRx Awarded First Prize in Annual Israel BIOMED Startup Competition | 111 | 1 |
May 23, 2016: Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression | 112 | 1 |
May 12, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 169th Annual Meeting of the American Psychiatric Association | 113 | 1 |
Feb 25, 2016: Intra-Cellular Therapies Provides Product Update | 114 | 2 |
Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch | 116 | 1 |
Dec 23, 2015: Intra-Cellular Therapies Reports Initiation of Patient Enrollment for ITI-007 Phase 3 Clinical Trials in Bipolar Depression | 116 | 1 |
Dec 16, 2015: NeuroRx Provides Clinical Development Update for Cyclurad, a Novel Treatment for Acute Suicidal Crisis in Bipolar Disorder | 117 | 1 |
Nov 16, 2015: Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch | 118 | 1 |
Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole | 119 | 1 |
Jul 22, 2015: Intra-Cellular Therapies Announces Phase 3 Clinical Development Program for the Treatment of Depressive Episodes Associated With Bipolar Disorder | 120 | 1 |
May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole | 120 | 1 |
Appendix | 121 | 2 |
Methodology | 121 | 1 |
Coverage | 121 | 1 |
Secondary Research | 121 | 1 |
Primary Research | 121 | 1 |
Expert Panel Validation | 121 | 1 |
Contact Us | 121 | 1 |
Disclaimer | 122 | 1 |